ResearcherEdinburgh Cancer ResearchNo recent work listed

Stefan Nicholas Symeonides

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9892-9314; OpenAlex author ID A5053055306. Sources: ClinicalTrials.gov.

Their work

Papers: 1
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2017: 1 paper, 1 trial

Papers 1

FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer. Co-author DOI 10.1186/s40425-017-0217-6 ↗

Trials 1

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) Principal investigator NCT02758587 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christian Ottensmeier · 1 shared trial, 2017 · strength 0.13
- Trial Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) NCT02758587 ↗
Dean Fennell · 1 shared trial, 2017 · strength 0.13
- Trial Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) NCT02758587 ↗
Jeff Evans · 1 shared trial, 2017 · strength 0.13
- Trial Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) NCT02758587 ↗
Vicky Coyle · 1 shared trial, 2017 · strength 0.13
- Trial Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) NCT02758587 ↗
Alan Serrels · 1 shared paper, 2017 · strength 0.12
- Paper FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer. DOI 10.1186/s40425-017-0217-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.